Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy
Status:
Recruiting
Trial end date:
2023-03-10
Target enrollment:
Participant gender:
Summary
Study of the efficiency of Béfizal® 200 mg in 14 adult patients with a LHON that occurred for
less than 5 years. Patient must have certain specific mutations